The Biomed Accelerates Profit Structure Improvement... Narrows Operating Losses

KOSDAQ-listed company The Biomed announced on May 15, 2025, that it reduced its deficit in the first quarter of this year.

On a consolidated basis, first-quarter revenue was approximately 2.426 billion KRW, representing a slight decrease compared to the same period last year. Gross profit reached 1.189 billion KRW. This marks a turnaround from a loss of about 1.269 billion KRW in the same period last year. This improvement is significant as it demonstrates a fundamental enhancement of the company's profit-generating structure.

The operating loss amounted to 2.188 billion KRW, narrowing from 6.546 billion KRW in the same period last year.

A company representative explained, "We are currently streamlining our organization and product lineup through a strategy of selection and concentration," and added, "We are also achieving positive results in our newly launched education business sector."

The Biomed plans to continue focusing on businesses with promising profitability to generate sustained results.

A representative from The Biomed stated, "Since the replacement of the management team in December last year, we have been able to achieve meaningful results," and added, "We will strive to enhance corporate value by strengthening the expertise of our existing in vitro diagnostics business and pursuing diversification into new businesses that can deliver significant outcomes."

On May 9, The Biomed changed its company name from Mikrobiomed to The Biomed (THE BIOMED). The name change reflects the company's commitment to a fresh start and business expansion. The new name encompasses the values of Therapy, Healthcare, Education, Biology, and Medicine.

This content was produced with the assistance of AI translation services.